Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
Answer first: operators build the case, payers do not
SUD operators will not get paid for longer, more complex synthetic-drug detox by waiting for Optum, Carelon, or a state Medicaid MCO to update its authorization grid. Operators have to push the case the other direction: document medical necessity beyond the ASAM Criteria 4th Edition defaults, request single-case agreements (SCAs) with enhanced per diems for xylazine, nitazene, tianeptine, and synthetic-benzodiazepine admissions, and pre-build utilization review appeal packages that translate atypical clinical courses into language a payer’s UR nurse can actually approve.
The drug supply has changed faster than any payer policy committee. The DEA’s May 12, 2026 Public Safety Advisory warns that law enforcement and public health officials are seeing fentanyl combined with highly potent substances such as xylazine, nitazenes, cychlorphine, and medetomidine, and notes that new nitazenes tend to be introduced when regulatory actions, enforcement, and drug scheduling put pressure on existing analogues, with the DEA reporting 22 unique nitazene compounds since 2020, 21 of which are listed as Schedule I controlled substances. DEA Detroit Special Agent in Charge Joseph O. Dixon put it bluntly: “The illicit drug supply is more unpredictable and more lethal than ever before.”
Meanwhile the payer-side authorization criteria still read like 2018 fentanyl. That gap is where operators are losing money on every admission they should be winning.
What the data actually says (and what payers are still missing)
CDC’s January 2026 NCHS Data Brief No. 549 reports that in 2024, 79,384 drug overdose deaths occurred, resulting in an age-adjusted rate of 23.1 deaths per 100,000, and that between 2023 and 2024 the drug overdose death rate involving synthetic opioids other than methadone dropped 35.6% (from 22.2 to 14.3). Good news at the surface. Underneath it, the clinical picture in the bed is harder, not easier.
Polysubstance is now the norm, and the adulterant profile is broader than any grid contemplates. The DEA advisory notes that drugs like xylazine and medetomidine are not opioids, meaning naloxone may not fully reverse their effects, complicating overdose response, and that xylazine has been linked to devastating soft tissue damage, infections, and prolonged sedation.
Tianeptine, the so-called gas-station heroin, is no longer a curiosity. A 2025 study in the Journal of Medical Toxicology found 892 single-substance tianeptine exposures reported to US poison centers from 2015 to 2023, with the rate of exposures increasing 1,400% from 2015 to 2023, including a 525% increase from 2018 to 2023. The same study reported that most exposures were associated with moderate (51.5%) or major (12.0%) effects, and 40.1% required medical admission, including 22.9% to a critical care unit.
Translation for the contracting team: a UR nurse looking at a payer grid that pays a 3-to-5 day opioid detox will deny day 6, 7, and 8, even when the patient is still actively withdrawing from xylazine and a nitazene cocktail. The COWS-driven authorization model does not describe the patient in the room anymore.
The operator-side playbook: SCAs, carve-outs, and parity arguments
At a 64-bed residential and withdrawal-management facility in Florida that AHS supports on payer strategy, our team rebuilt the admission packet last quarter specifically for synthetic-drug cases. Clinicians stopped sending payers a generic ASAM 4th Edition dimensional summary. We started sending a structured medical-necessity narrative: confirmed adulterant exposure on toxicology, COWS plus an alpha-2 withdrawal assessment, autonomic instability data points, and a stated expected length of stay tied to the specific clinical course. Authorization approvals on extended stays jumped, and days in AR on those cases dropped by roughly 11 days.
Four moves operators should make now:
- Request a single-case agreement before admission, not after the denial. Lead with toxicology (xylazine, nitazene, tianeptine, bromazolam, or other designer benzo), expected length of stay, and a proposed per diem 15 to 35 percent above the standard residential or residential withdrawal management rate. Reference the SAMHSA TIP 63 framework and the ASAM Criteria 4th Edition dimensional assessment in the body of the request.
- Pursue rate carve-outs in your next contract cycle. Florida AHCA-contracted MCOs, New Jersey DMAHS plans, and MassHealth ACOs have all entertained acuity-adjusted per diems under their 1115 SUD demonstrations when the operator brings clean outcomes data. A flat per diem set in 2021 does not cover a 2026 xylazine admission.
- Cite MHPAEA directly in commercial denials. The 2024 MHPAEA Report to Congress states that EBSA has requested and reviewed comparative analyses for hundreds of NQTLs, obtained corrections that removed impermissible MH/SUD treatment barriers for more than 7.6 million participants in over 72,000 plans, and ensured payment of wrongfully denied MH/SUD claims. EBSA is currently devoting nearly 25 percent of its enforcement program to work focusing on MHPAEA NQTLs. When a commercial payer applies a tighter concurrent review standard to a polysubstance synthetic-drug detox than it would to a comparable medical/surgical admission, that is an NQTL parity argument, and it belongs in your appeal letter, not in a footnote.
- Build the UR appeal scaffold once, use it every time. Pre-write the parity citation, the ASAM dimensional logic, the toxicology attachment, and the physician peer-to-peer talking points. Train the UR coordinator to file within 24 hours of an adverse determination.
Operators who can produce outcomes data on the synthetic-drug cohort have the strongest possible footing in any contract negotiation or appeal.
Compliance side: the documentation has to defend the clinical reality
Higher-acuity admissions invite audit risk if the chart does not match the level of care. At a residential SUD program in Kentucky that AHS worked with from acquisition through licensure, the clinical leadership rewrote admission criteria and physician progress notes specifically to capture xylazine and nitazene exposure, autonomic instability, wound-care needs, and co-occurring sedative-hypnotic withdrawal. That documentation now does double duty: it defends medical necessity to the payer, and it satisfies state licensing surveyors looking at whether the residential level of care is appropriate for the acuity in the building.
Three compliance-side guardrails for operators stepping into synthetic-drug acuity:
- Confirm your license actually covers the acuity you are admitting. Under the ASAM Criteria 4th Edition, residential withdrawal management is the appropriate residential detox setting. If a patient genuinely needs medically managed inpatient care, a free-standing residential license does not stretch that far. State DOH and DCF surveyors will ask.
- Update your medical director’s standing orders and protocols for alpha-2 agonist withdrawal, nitazene reversal considerations (including that nitazenes and cychlorphine might require several doses of naloxone to be effective), and synthetic-benzodiazepine taper. Your internal protocol has to be explicit and defensible because the federal and state guidance is still catching up to the street supply.
- Bake FWA controls around the new revenue. Enhanced per diems and SCAs draw payer SIU attention. Clean claim rate, denial rate by payer, and documentation completeness belong on the QAPI dashboard, not buried in the RCM vendor’s monthly report.
The Joint Commission accreditation surveys AHS supported in May 2026, covering five facilities across three states and three levels of care, every one of them turned on whether the clinical record could defend what the contracting team was billing. The two functions cannot operate in separate buildings anymore.
What to do this quarter
Operators who move now will out-earn operators who wait for the payer grid to catch up. Pull the last 90 days of denied residential and withdrawal-management claims, sort by toxicology (xylazine, nitazene, tianeptine, bromazolam), and build the appeal template around what you already had in the chart. Ask your top three commercial payers for their MHPAEA comparative analysis in writing; the 2024 Report to Congress makes clear EBSA states that “non-compliance” with the requirement to provide a NQTL comparative analysis “remains widespread”. Then take your two highest-volume Medicaid MCOs into a contracting conversation about acuity-adjusted per diems, with your own outcomes data on synthetic-drug admissions in hand.
Two things to stop doing today: stop letting UR coordinators file appeals without a parity citation, and stop admitting patients whose clinical acuity outruns your license. Both are recoupment risk. Both are fixable this week.
Frequently asked questions
How do we justify a longer detox length of stay for xylazine or nitazene exposure when the payer’s grid still reflects standard opioid withdrawal timelines?
Submit a medical-necessity narrative that pairs toxicology confirmation with a documented withdrawal trajectory, cite the delayed onset and prolonged course associated with fentanyl-plus-xylazine mixtures, and reference the ASAM Criteria 4th Edition dimensional assessment supporting continued stay. Pre-load the chart with autonomic vital-sign trends, COWS plus an alpha-2 withdrawal scale, and physician documentation of why the patient does not yet meet step-down criteria. The DEA’s May 2026 advisory documents that xylazine is not an opioid and that naloxone may not fully reverse its effects, which supports an atypical clinical course argument on the appeal.
What belongs in a single-case agreement (SCA) request for a complex synthetic-drug admission?
Patient-specific toxicology, the proposed level of care, expected length of stay, the proposed per diem with a clear delta from your standard rate, co-occurring conditions (wound care, cardiovascular instability, psychiatric acuity), and a statement that in-network options do not exist or cannot provide the required level of care within a reasonable geographic and clinical window. Attach your accreditation status, licensure, and outcomes data. Get it signed before admission whenever possible.
Can MHPAEA help when commercial payers deny extended residential SUD stays for polysubstance synthetic cases?
Yes. If the plan applies more restrictive concurrent review standards, prior authorization criteria, or medical-necessity thresholds to SUD residential than to comparable medical/surgical inpatient admissions, that is an NQTL question. The 2024 MHPAEA Report to Congress confirms EBSA has obtained corrections that benefited more than 7.6 million participants in over 72,000 plans, and the same report indicates EBSA is devoting nearly 25 percent of its enforcement program to NQTL work. Cite the parity framework in the appeal, and if the denial pattern is systemic, escalate to DOL EBSA or the state insurance department.
What credentialing or licensing exposure do we create by admitting higher-acuity synthetic-drug patients to a residential level of care?
Two big ones. First, your residential or residential-withdrawal-management license has scope limits; admitting patients who clinically need medically managed inpatient care can trigger a state DOH or DCF citation. Second, your payer credentialing application and contract describe the populations you serve and the services you provide. If you start billing higher-acuity codes or pursuing SCAs for clinical populations outside your credentialed scope, you create payer audit and recoupment exposure. Update your medical staff bylaws, scope-of-service documents, and credentialing files before the case mix shifts, not after.
References
- DEA Public Safety Advisory: Heightened Threat of Fentanyl Mixed with Emerging Synthetic Drugs (May 12, 2026)
- CDC NCHS Data Brief No. 549: Drug Overdose Deaths in the United States, 2023-2024 (January 2026)
- Quadir M, et al. Tianeptine Exposures Reported to United States Poison Centers, 2015-2023. Journal of Medical Toxicology, 2025
- 2024 MHPAEA Report to Congress (U.S. Departments of Labor, HHS, and Treasury)
- DOL Press Release: 2024 MHPAEA Report to Congress (January 17, 2025)
- DEA Detroit statement from SAC Joseph O. Dixon (May 13, 2026)